Rising awareness about maternal mental health and increasing efforts to reduce the stigma associated with mental health issues among pregnant women and new mothers are major growth drivers for the maternal mental health market. Additionally, the availability of advanced diagnostic tools and therapeutic options for maternal mental health conditions is expected to further drive market growth.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Disease Indication, Therapy |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Therapy Mama, Canopie, Pfizer Inc, Viatris, GlaxoSmithKline, Alembic Pharmaceuticals Limited, Mallinckrodt, Sage Therapeutics,, Bausch Health Companies, Magellan Health, |
Lack of healthcare infrastructure and resources in developing countries, along with the high cost of mental health services, are major restraints in the maternal mental health market. Moreover, limited access to specialized maternal mental health professionals and services in certain regions also poses a challenge to market growth.